Tags

Type your tag names separated by a space and hit enter

Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study.
Surg Endosc. 2002 Jul; 16(7):1087-90.SE

Abstract

BACKGROUND

Postoperative nausea and vomiting are observed in increased frequency after laparoscopic surgery. This study was performed in order to compare the efficacy of two 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, ondansetron and tropisetron, in preventing postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy.

METHODS

Using a randomized, double-blind study design, 87 ASA I and II patients scheduled for laparoscopic cholecystectomy were randomly assigned to receive 4 mg ondansetron (Group A, n = 29), 5 mg tropisetron (Group B, n = 31), or placebo (Group C, n = 27) intravenously (IV) before induction of anesthesia. The end points evaluated were frequency of nausea, nausea intensity rated on a scale from 1 (mild) to 5 (most severe), frequency of vomiting, and need for rescue antiemetics. These parameters were measured immediately after surgery (0 h), at 3 h, 6 h, and 12 h postoperatively.

RESULTS

The frequency of nausea was significantly higher in group A (31.2%) compared to group B (14%) at 12 h postoperatively (p <0.01). However, patients of group A had significantly lower nausea scores at 3 h postoperatively compared to group B. Postoperative vomiting occurred in 13.8% of patients in group A and 9.6% of patients in group B throughout the whole study period (p = n.s.). The need for rescue antiemetics was similar between groups A and B. Both groups were superior to placebo concerning all studied parameters.

CONCLUSION

Our results show that ondansetron may be more effective in controlling nausea intensity during the first 3 h after laparoscopic cholecystectomy, while tropisetron has a longer-acting activity, with a major impact on nausea frequency at 12 h postoperatively.

Authors+Show Affiliations

Department of Anesthesiology, G. Gennimatas Hospital, Ethnikis Aminis 41, 546 35 Thessaloniki, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12165828

Citation

Argiriadou, H, et al. "Tropisetron Vs Ondansetron for Prevention of Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: a Randomized Double-blind, Placebo-controlled Study." Surgical Endoscopy, vol. 16, no. 7, 2002, pp. 1087-90.
Argiriadou H, Papaziogas B, Pavlidis T, et al. Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study. Surg Endosc. 2002;16(7):1087-90.
Argiriadou, H., Papaziogas, B., Pavlidis, T., Parlapani, A., Georgiou, M., Papagiannopoulou, P., & Papaziogas, T. (2002). Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study. Surgical Endoscopy, 16(7), 1087-90.
Argiriadou H, et al. Tropisetron Vs Ondansetron for Prevention of Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: a Randomized Double-blind, Placebo-controlled Study. Surg Endosc. 2002;16(7):1087-90. PubMed PMID: 12165828.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study. AU - Argiriadou,H, AU - Papaziogas,B, AU - Pavlidis,T, AU - Parlapani,A, AU - Georgiou,M, AU - Papagiannopoulou,P, AU - Papaziogas,T, Y1 - 2002/04/09/ PY - 2001/10/10/received PY - 2001/11/26/accepted PY - 2002/8/8/pubmed PY - 2002/9/17/medline PY - 2002/8/8/entrez SP - 1087 EP - 90 JF - Surgical endoscopy JO - Surg Endosc VL - 16 IS - 7 N2 - BACKGROUND: Postoperative nausea and vomiting are observed in increased frequency after laparoscopic surgery. This study was performed in order to compare the efficacy of two 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, ondansetron and tropisetron, in preventing postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy. METHODS: Using a randomized, double-blind study design, 87 ASA I and II patients scheduled for laparoscopic cholecystectomy were randomly assigned to receive 4 mg ondansetron (Group A, n = 29), 5 mg tropisetron (Group B, n = 31), or placebo (Group C, n = 27) intravenously (IV) before induction of anesthesia. The end points evaluated were frequency of nausea, nausea intensity rated on a scale from 1 (mild) to 5 (most severe), frequency of vomiting, and need for rescue antiemetics. These parameters were measured immediately after surgery (0 h), at 3 h, 6 h, and 12 h postoperatively. RESULTS: The frequency of nausea was significantly higher in group A (31.2%) compared to group B (14%) at 12 h postoperatively (p <0.01). However, patients of group A had significantly lower nausea scores at 3 h postoperatively compared to group B. Postoperative vomiting occurred in 13.8% of patients in group A and 9.6% of patients in group B throughout the whole study period (p = n.s.). The need for rescue antiemetics was similar between groups A and B. Both groups were superior to placebo concerning all studied parameters. CONCLUSION: Our results show that ondansetron may be more effective in controlling nausea intensity during the first 3 h after laparoscopic cholecystectomy, while tropisetron has a longer-acting activity, with a major impact on nausea frequency at 12 h postoperatively. SN - 1432-2218 UR - https://www.unboundmedicine.com/medline/citation/12165828/Tropisetron_vs_ondansetron_for_prevention_of_postoperative_nausea_and_vomiting_after_laparoscopic_cholecystectomy:_a_randomized_double_blind_placebo_controlled_study_ L2 - https://dx.doi.org/10.1007/s00464-001-9191-6 DB - PRIME DP - Unbound Medicine ER -